Schizophrenia  >>  Risperdal Consta (risperidone depot formulation)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Risperdal Consta (risperidone depot formulation) / J&J
NCT02091388: Bioavailability of LY03004 and Risperdal® Consta®

Completed
1
108
US
LY03004, Risperdal® Consta®
Luye Pharma Group Ltd.
Schizophrenia, Schizoaffective Disorder
01/15
01/15
NCT02186769: An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

Completed
1
16
US
Risperdal® Consta®, LY03004
Luye Pharma Group Ltd.
Schizophrenia, Schizoaffective Disorder
04/15
04/15

Download Options